Gökhan UÇAR, Yakup ERGÜN, Yusuf AÇIKGÖZ, Selin Aktürk ESEN, Özlem AYDIN, Ercan Aydın KARAHALİLOĞLU, İrem SARICANBAZ, Doğan UNCU

Opere Pankreas Adenokanserli Hastalarda Kemoterapiye Kemoradyoterapi Eklemenin Katkısı

Giriş: Pankreas kanserleri kansere bağlı ölüm nedenleri arasında dördüncü sırada yer almaktadır. Genel sağ kalımı iyileştirmek adjuvan kemoterapi (KT) ve kemoradyoterapi (KRT) çalışmaları yapılmaktadır. Biz de pankreas kanserinde retrospektif olarak adjuvan tedavide kemoradyoterapinin etkisini araştırmayı amaçladık.Yöntemler: Ocak 2010 ve Aralık 2017 tarihleri arasında merkezimizde pankreas kanseri nedeniyle opere edilen ve sonrasında adjuvan tedavi verilen 90 hastanın verileri retrospektif olarak tarandı. Hasta dosyalarından yaş, cinsiyet, ECOG performans durumu, vücut kitle indeksi (VKİ), evre, adjuvan dönemde aldığı tedaviler, KRT alıp almadığı, incelenerek kayıt edildi.Bulgular: Çalışmaya toplam 46 hasta dahil edildi. KRT kolunda ortanca GSK 16,9 ay (7,8-2,63 ay) iken KT kolunda ise 17,6 ay olup iki grup arasında istatistiksel olarak anlamlı fark saptanmadı( p=0,875). Ortanca DFS,KRT kolunda 12,2 ay iken KT kolunda 7,2 ay saptandı(p:0,3).Tartışma: Sonuç olarak, literatürde yapılan son çalışmalarla uyumlu olarak bizim çalışmamızda da pankreas kanserli hastalarda adjuvan tedavide kemoterapiye kemoradyoterapi eklemenin genel sağ kalım ve hastalıksız sağ kalıma katkısı gösterilemedi.

The Contribution of Adding Chemoradiotherapy to Adjuvant Chemotherapy in Pancreatic Cancer Patients

Introduction: Pancreatic cancers rank fourth among the causes of cancer-related death. Adjuvant chemotherapy (CT) and chemoradiotherapy (CRT) studies are conducted to improve overall survival. We aimed to investigate the effect of chemoradiotherapy in adjuvant therapy retrospectively in pancreatic cancer. Method: The data of 90 patients who were operated in our center for pancreatic cancer between January 2010 and December 2017, and who were given adjuvant treatment afterwards, were retrospectively reviewed. Treatments were recorded by examining whether they received CRT. Results: A total of 46 patients were included in the study. While the median GSK in the CRT arm was 16.9 months (7.8- 2.63 months), it was 17.6 months in the CT arm and there was no statistically significant difference between the two groups (p = 0.875). 7.2 months were detected in the CT arm (p: 0.3) Conclusion: Consequently, in our study, in accordance with the latest studies in the literature, the contribution of adding chemoradiotherapy to chemotherapy in adjuvant therapy in patients with pancreatic cancer, overall survival and disease-free survival could not be demonstrated.

PDF

___

1.Danıs R, Bayan K, Yılmaz Ş, Altıntas A. ThePancreatic Cancer Cases in Dicle UniversityDepartment of Gastroenterology in the Last TenYears. Dicle Med J. 2004; 31: 58-61.
2.Ergun Y, Ozdemir NY, Guner EK, et al . Comparisonof Gemcitabine monotherapy with Gemcitabine andCisplatin combination in metastatic pancreaticcancer: a retrospective analysis. J BUON. 2018;23:116-21.
3.Rahib L, Smith BD, Aizenberg R, Rosenzweig AB,Fleshman JM, Matrisian LM. Projecting cancerincidence and deaths to 2030: the unexpectedburden of thyroid, liver, and pancreas cancers in theUnited States. Cancer Res. 2014; 74:2913-21.
4.Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-17.
5.Gurusamy KS, Kumar S, Davidson BR, Fusai G.Resection versus other treatments for locallyadvanced pancreatic cancer. Cochrane DatabaseSyst Rev. 2014; CD010244.
6.Hishinuma S, Ogata Y, Tomikawa M, et al. Patternsof recurrence after curative resection of pancreaticcancer, based on autopsy findings. J GastrointestSurg. 2006; 10:511-8.
7.Neoptolemos JP, Dunn JA, Stocken DD, et al.Adjuvant chemoradiotherapy and chemotherapy inresectable pancreatic cancer: a randomisedcontrolled trial. Lancet. 2001; 358:1576-85.
8.Dobiasch S, Goerig NL, Fietkau R, Combs SE.Essential role of radiation therapy for the treatmentof pancreatic cancer: Novel study concepts and established treatment recommendations. Strahlenther Onkol. 2018; 194:185-95.
9.Springfeld C, Jäger D, Büchler MW, et al.Chemotherapy for pancreatic cancer. Presse Med.2019;48(3 Pt 2):e159-e174.
10.Kalser MH, Ellenberg SS. Pancreatic cancer.Adjuvant combined radiation and chemotherapyfollowing curative resection. Arch Surg.1985;120:899–903.
11.Further evidence of effective adjuvant combinedradiation and chemotherapy following curativeresection of pancreatic cancer. GastrointestinalTumor Study Group. Cancer. 1987; 59: 2006-10.
12.Klinkenbijl JH, Jeekel J, Sahmoud T, et al.Adjuvant radiotherapy and 5-fluorouracil aftercurative resection of cancer of the pancreas andperiampullary region: phase III trial of the EORTCgastrointestinal tract cancer cooperative group. AnnSurg. 1999; 230:776-82; discussion 782-4.
13.Helvacı K, Üyetürk Ü, Sönmez Ö, Türker İ, ArslanÜY. Evaluation Of Demographic AndClinicopathological Characteristics Of PanreaticAdenocarcinoma Patients. Acta Oncol Tur. 2016;49:91-101.